Hints and tips:
Related Topics
...He joined US firm Biogen and then Genentech....
...Tessier-Lavigne, who previously ran Rockefeller University and was a senior research executive at Genentech, the pharma group owned by Roche, had stressed priorities at Stanford including the need for a...
...Successfully implemented at the helm of Genentech, this rid the months-long process to allocate budgets and freed up funds to be spent on innovation. “I’ve seen it before....
...The veterans of Genentech, Chiron and Cetus in the San Francisco Bay Area have started hundreds of companies. Likewise, in Boston with Genzyme, Biogen, etc....
...“If you go to that part of the world, almost anyone who is anyone in that field has been in and out of Genentech. We need to think about how Genentech was successful....
...The results are a boost for Roche’s Genentech. In 2016, it agreed to pay BioNTech a hefty $310mn to collaborate on its cancer programme....
...The Genentech investment shows why: Kleiner Perkins made a return of 42 times on its first investment fund after Genentech went public in 1980 at a heady valuation....
...Those companies include: Google parent Alphabet, Altria, American Airlines, AT&T, Boeing, Comcast, CVS Health, Delta, Eli Lilly, FedEx, Ford, Genentech, Lockheed Martin, Pfizer, PG&E, PwC, Raytheon, T-Mobile...
...The former Genentech chief medical officer pushed a strategy led by human genetics and formed partnerships in the Bay Area, where he is based....
...Actemra is made by the biotech company Genentech, a subsidiary of Switzerland’s Roche....
...In 2019, Genentech, the company’s US biotech subsidiary, shifted from distillation to cold-membrane filtering for the pure water used in its labs and factories, sharply cutting the energy involved....
...After a protracted battle, Roche took over US biotech Genentech in 2009 for $47bn....
...Bloomberg, which first broke the news of the stake on Tuesday, reported that SoftBank believes Roche’s Genentech division is significantly undervalued....
...SoftBank has quietly built a $5bn stake in Roche, believing the Swiss pharmaceutical group’s Genentech data-based drug discovery division is highly undervalued, Bloomberg reported....
...Over dinner at Heiliggeist, a nearly 800-year-old church-turned-restaurant on the banks of the river Rhine, and joined by scientists from Swiss pharmaceutical company Genentech, the group discussed the potential...
...A key moment came in 2009 when he was appointed CEO of Genentech, the California-based biotechnology company which had been acquired by Swiss pharma group Roche....
...Investors sometimes compare Walmsley to rival AstraZeneca’s Pascal Soriot, who had a career in pharma including leading Genentech before taking the helm of the Anglo-Swedish company and turning it into a...
...The company is still benefiting from Genentech’s oncology expertise. Mr Schwan agrees that he has profited from decisions made by predecessors....
...In addition to Chugai’s plant in Japan, special permission has been granted for Roche unit Genentech’s site in Oregon to undertake part of the drug production process....
...Shares in Roche, whose subsidiary Genentech makes gantenerumab, were flat....
...Almost a year earlier he had persuaded Arthur Levinson, the driving force behind the biotech giant Genentech and chairman of Apple, to oversee the new business and lined up $1.5bn in funding pledges — half...
...California based Hal Barron, head of R&D, was plucked from Google’s longevity start-up Calico, and had been chief medical officer at Genentech and Roche....
...Genentech dished out a healthy $300m earlier this year to access part of Adaptive’s T-cell receptor platform, and the two companies are targeting a broad range of cancers....
...Mr Soriot’s term for his own leadership style is “casual intensity”, an approach he dates back to a period as chief executive of Genentech, the Californian biotech, whose laid-back and collaborative internal...
International Edition